Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
Jackson T BowersJacob L AnnaSteven M BairKaitlin AnnunzioNarendranath EpperlaJerrin Joy PullukkaraSameh GaballaMichael A SpinnerShuning LiMarcus R MessmerJoseph Dan Khoa NguyenEmily C AyersCharlotte B WagnerBoyu HuMengyang DiScott F HuntingtonFateeha FurqanNirav N ShahChristina ChenHatcher J BallardMitchell E HughesElise A ChongSunita D NastaStefan K BartaDaniel J LandsburgJakub SvobodaPublished in: Blood advances (2023)
In the non-trial setting, BV+AVD was associated with a high incidence of PN. In our cohort, which includes patients who would not have been eligible for the pivotal ECHELON-1 trial, BV discontinuation rates were higher than previously reported, but 2-year outcomes remain comparable.